Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-FULL
jRCTs071200046Phase 2Completed
- Start
- Feb 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, cisplatin, carboplatin, pemetrexed and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: 12-month progression-free survival rate. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071200046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200046.